Clinical Trial Results:
An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvastatin and Pravastatin in the Treatment of Subjects with Dysbetalipoproteinemia (Fredrickson Type III Hyperlipoproteinemia)
Summary
|
|
EudraCT number |
2005-002889-11 |
Trial protocol |
NO |
Global completion date |
14 Feb 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
09 May 2021
|
First version publication date |
25 Nov 2018
|
Other versions |
v1 (removed from public view) |
Version creation reason |
|
Summary report(s) |
redacted CSR synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.